Medtronic announces FDA approval of minimally invasive device to treat hypertension
Date postedNovember 20, 2023
DUBLIN, Nov. 17, 2023 / PRNewswire / — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Symplicity Spyral™ renal denervation (RDN) system, also known as the Symplicity™ blood pressure procedure, for the treatment of hypertension. With this approval, Medtronic will immediately begin commercialization.